|
Market Closed -
Nasdaq Stockholm
17:00:00 28/10/2026 GMT
|
5-day change | 1st Jan Change | ||
| 7.600 SEK | +0.13% |
|
+11.44% | -43.70% |
| 10-20 | 15 stocks have so far today hit new 52-week lows on the Stockholm Stock Exchange | FW |
| 10-13 | Vivesto to present positive study data for Paccal Vet at veterinary congress | FW |
| Market Cap | 84.14M 8.48M 7.61M 7.04M 6.37M 11.91M 808M 12.05M 33.51M 423M 31.84M 31.17M 1.34B | P/E 2026 * |
-2.52x | P/E 2027 * | -2.1x |
|---|---|---|---|---|---|
| Enterprise Value | 76.14M 7.68M 6.89M 6.37M 5.77M 10.78M 731M 10.91M 30.33M 383M 28.81M 28.2M 1.21B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | - |
| Free-Float |
52.67% | Yield 2026 * |
-
| Yield 2027 * | - |
Nasdaq StockholmSEK
| Markets | Quality | ||
|---|---|---|---|
Nasdaq Stockholm
| VIVE | Delayed | |
Deutsche Boerse AG
| OMA | Delayed | |
|
CBOE
| 0N4A | Real-time | |
|
CBOE
| OASMs | Real-time | |
|
Börse Stuttgart
| OMA | Delayed |
Last Transcript: Vivesto AB
| 1 day | +0.13% | ||
| 1 week | +11.44% | ||
| Current month | -9.63% | ||
| 1 month | -12.44% | ||
| 3 months | -13.14% | ||
| 6 months | -7.54% | ||
| Current year | -43.70% |
| 1 week | 6.83 |  | 7.7 |
| 1 month | 6.5 | | 8.77 |
| Current year | 6.5 | | 19.5 |
| 1 year | 6.5 | | 27.3 |
| 3 years | 6.5 | | 90.6 |
| 5 years | 6.5 | | 302.9 |
| 10 years | 6.5 | | 1,670 |
| Manager | Title | Age | Since |
|---|---|---|---|
Erik Kinnman
CEO | Chief Executive Officer | 68 | 22/01/2023 |
Björn Svanström
DFI | Director of Finance/CFO | 55 | 30/06/2026 |
| Chief Tech/Sci/R&D Officer | 39 | 31/12/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 46 | 24/05/2022 | |
Hege Hellstrom
BRD | Director/Board Member | 61 | 25/09/2019 |
Pål Ryfors
BRD | Director/Board Member | 43 | 24/05/2022 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 25/03/22 | Buy | Chief Executive Officer | 12,200 | 0.0027% | ||
| 24/03/22 | Others | Chairman | 120,000 | 0.0268% | ||
| 20/12/21 | Free | Chief Executive Officer | 2,250,000 | 0.5018% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.13% | +11.44% | -66.88% | -64.98% | 8.46M | |
| +0.50% | +1.38% | +57.09% | +129.96% | 1,143B | |
| +0.86% | +5.14% | +45.00% | +86.15% | 647B | |
| -0.14% | +0.42% | +25.69% | +105.85% | 506B | |
| -0.05% | +1.73% | +52.74% | +67.74% | 384B | |
| -0.63% | -5.97% | +61.93% | +37.06% | 350B | |
| +0.34% | +1.84% | +30.70% | +54.27% | 293B | |
| -0.45% | +1.19% | +2.89% | +26.08% | 265B | |
| +0.87% | +3.08% | +54.69% | +72.74% | 242B | |
| +0.08% | +3.67% | +35.05% | +107.78% | 197B | |
| Average | +0.15% | +1.62% | +29.89% | +62.27% | 402.75B | |
| Weighted average by Cap. | +0.25% | +0.71% | +44.50% | +89.02% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -31M -3.13M -2.8M -2.59M -2.35M -4.39M -298M -4.44M -12.35M -156M -11.73M -11.48M -495M | -40M -4.03M -3.62M -3.35M -3.03M -5.66M -384M -5.73M -15.93M -201M -15.13M -14.82M -638M |
| Net Debt | -8M -807K -724K -669K -606K -1.13M -76.82M -1.15M -3.19M -40.2M -3.03M -2.96M -128M | -17M -1.71M -1.54M -1.42M -1.29M -2.41M -163M -2.43M -6.77M -85.43M -6.43M -6.3M -271M |
Employees
4
Sector
Pharmaceuticals
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/10/26 | SEK 7.600 | +0.13% | 10,810 |
| 27/10/26 | SEK 7.590 | +4.83% | 5,068 |
| 26/10/26 | SEK 7.240 | +2.99% | 3,277 |
| 23/10/26 | SEK 7.030 | -2.63% | 4,968 |
| 22/10/26 | SEK 7.220 | +5.87% | 6,515 |
Annual profits - Rate of surprise
- Stock Market
- Stocks
- VIVE Stock
Select your edition
All financial news and data tailored to specific country editions
